Little hope in TIGIT trials to date

As expected, TIGIT addition to PD1 failed to beat chemo in second-line patients.

The failure of Merck’s TIGIT+PD1 combo to beat second line chemo therapy in non-small cell lung cancer appears to replicate the data seen from Merck’s phase 1 digit PD1 combination trial where patients who were refractory to PD1 only saw a 3% response rate and a progression free survival below that seen with typical chemotherapy. Given most patients would have had received PD1 therapy in first line, we do not see this failure as unexpected.

Gilead/Arcus 1st line TIGIT data also appears equivocal in our view...